Brandaris

Delix

This company develops non-hallucinogenic neuroplasticity-promoting medicines to treat neuropsychiatric and neurodegenerative conditions for patients with brain disorders.

Draig Therapeutics

The company develops neuromodulators and receptor potentiators for patients with major depressive disorder and other neuropsychiatric conditions.

Elkedonia

This biotechnology company develops neuroplastogen treatments for patients suffering from treatment-resistant depression and other neuropsychiatric disorders.

Syremis

This biopharmaceutical company develops oral small-molecule medicines for patients with schizophrenia, major depressive disorder, and other serious mental health conditions.

Syremis Therapeutics

This biopharmaceutical company develops small-molecule oral medicines for patients with neuropsychiatric conditions, including schizophrenia, major depressive disorder and bipolar depression.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Cyclerion Therapeutics

This biopharmaceutical company develops neuropsychiatric therapies for patients with treatment-resistant depression and other neurodegenerative diseases.

Delix Therapeutics

This biotechnology company develops non-hallucinogenic neuroplasticity-promoting medicines to treat patients with neuropsychiatric and neurodegenerative conditions.